Physician profile
Steven E Silver
NPI 1114970225
$3,997.80
in general payments reported to CMS, 2019-2025
26 companies · $776 in 2025
The $776 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $375 · 2021: $449 · 2022: $336 · 2023: $285 · 2024: $670 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,730.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,341.00 | 2019-2025 | Aveir, Hi-Torque Advance, Navitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $607.12 | 2019-2025 | Lifevest |
| Amgen INC. | $315.55 | 2019-2025 | Repatha, Repatha |
| Impulse Dynamics (USA) INC. | $241.21 | 2024-2025 | Optimizer |
| Novartis Pharmaceuticals Corporation | $239.74 | 2019-2025 | |
| Pfizer INC. | $236.64 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $171.08 | 2020-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $148.56 | 2025 | Uptravi |
| Janssen Pharmaceuticals, INC | $101.51 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $95.82 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.45 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $66.66 | 2024-2025 | |
| W. L. Gore & Associates, INC. | $63.75 | 2019-2020 | |
| Amarin Pharma, INC. | $51.21 | 2019-2020 | |
| Kerecis Limited | $49.90 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $34.41 | 2023-2025 | Auryon Laser System 100-120 Vac |
| Cardiva Medical, INC. | $22.06 | 2019 | |
| Atricure, INC. | $17.74 | 2019 | |
| Daiichi Sankyo INC. | $17.04 | 2022 | |
| Inspire Medical Systems, INC. | $17.02 | 2024 | Inspire |
| Kiniksa Pharmaceuticals, Ltd. | $16.81 | 2023 | Arcalyst |
| Regeneron Pharmaceuticals, INC. | $16.80 | 2019 | |
| Bridgebio Pharma, INC. | $16.62 | 2025 | Attruby |
| Cvrx, INC. | $15.95 | 2024 | Barostim Neo System |
| Acarix USA INC. | $12.80 | 2024 | Cadscor System |
| Arbor Pharmaceuticals, INC. | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.